- Home
- IONS vs ALLE Comparison
IONS vs ALLE Comparison
Compare IONS & ALLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IONS | ALLE |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 13.9B |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | IONS | ALLE |
|---|---|---|
| Price | $76.87 | $140.83 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 22 | 8 |
| Target Price | $90.14 | ★ $171.13 |
| AVG Volume (30 Days) | ★ 1.8M | 700.9K |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 1.50% |
| EPS Growth | ★ 21.71 | 9.09 |
| EPS | N/A | ★ 7.44 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.43 |
| Revenue Next Year | $76.97 | $4.60 |
| P/E Ratio | ★ N/A | $19.78 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.90 | $122.14 |
| 52 Week High | $86.74 | $183.11 |
Technical Indicators
Market Signals| Indicator | IONS | ALLE |
|---|---|---|
| Relative Strength Index (RSI) | 55.99 | 39.58 |
| Support Level | $75.66 | $139.81 |
| Resistance Level | $82.85 | $167.42 |
| Average True Range (ATR) | 2.32 | 3.62 |
| MACD | 0.62 | 0.78 |
| Stochastic Oscillator | 90.62 | 25.59 |
Price Performance
Historical ComparisonAbout IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
About ALLE Allegion plc
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.